Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

A randomized, phase 2 trial compared the NVX-CoV2373 nanoparticle vaccine with placebo in participants in South Africa, including 30% who were seropositive at baseline. Overall vaccine efficacy was 49.4%, with the B.1.351 variant identified in more than 90% of isolates.

Saved in:
Bibliographic Details
Published inNew England Journal of Medicine Vol. 384; no. 20; pp. 1899 - 1909
Main Authors Shinde, Vivek, Bhikha, Sutika, Hoosain, Zaheer, Archary, Moherndran, Bhorat, Qasim, Fairlie, Lee, Lalloo, Umesh, Masilela, Mduduzi S.L, Moodley, Dhayendre, Hanley, Sherika, Fouche, Leon, Louw, Cheryl, Tameris, Michele, Singh, Nishanta, Goga, Ameena, Dheda, Keertan, Grobbelaar, Coert, Kruger, Gertruida, Carrim-Ganey, Nazira, Baillie, Vicky, de Oliveira, Tulio, Lombard Koen, Anthonet, Lombaard, Johan J, Mngqibisa, Rosie, Bhorat, As’ad E, Benadé, Gabriella, Lalloo, Natasha, Pitsi, Annah, Vollgraaff, Pieter-Louis, Luabeya, Angelique, Esmail, Aliasgar, Petrick, Friedrich G, Oommen-Jose, Aylin, Foulkes, Sharne, Ahmed, Khatija, Thombrayil, Asha, Fries, Lou, Cloney-Clark, Shane, Zhu, Mingzhu, Bennett, Chijioke, Albert, Gary, Faust, Emmanuel, Plested, Joyce S, Robertson, Andreana, Neal, Susan, Cho, Iksung, Glenn, Greg M, Dubovsky, Filip, Madhi, Shabir A
Format Journal Article Web Resource
LanguageEnglish
Published United States Massachusetts Medical Society 20.05.2021
Subjects
Adverse events
CD4 antigen
Coronaviruses
COVID-19
COVID-19 vaccines
Data collection
Disease transmission
Genomes
HIV
Human immunodeficiency virus
Hypothesis testing
Infections
Influenza
Lymphocytes T
Nanoparticles
Pandemics
Placebos
Proteins
Severe acute respiratory syndrome coronavirus 2
Spike protein
Statistical analysis
Surveillance
Vaccine efficacy
Vaccines
Viruses
Vital signs
South Africa
Online AccessGet full text

Cover

More Information
Summary:A randomized, phase 2 trial compared the NVX-CoV2373 nanoparticle vaccine with placebo in participants in South Africa, including 30% who were seropositive at baseline. Overall vaccine efficacy was 49.4%, with the B.1.351 variant identified in more than 90% of isolates.
Bibliography:This is an Author Final Manuscript, which is the version after external peer review and before publication in the Journal. The publisher’s version of record, which includes all New England Journal of Medicine editing and enhancements, is available at 10.1056/NEJMoa2103055.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2103055